Translational bioinformatics has been a new science that uses to transform huge volumes of molecular targets into therapeutic therapies. The bioinformatical approach pinpoints a better understanding of disease processes by combining genetic, phenomic, and environmental data. Our summary integrates several explanations from diverse publications were combined to construct pathways that depict the expression of gene mutations in driving a variety of diseases. The study involves literatures indexed by Scopus and Pub Med, the search uses a combination of the following keyword variants; "HaploReg" AND "genomic", "HaploReg" AND "repurposing drug". This study only used original articles in English which were peer reviewed journals published in 2022. Thus, the screening results of library sources were narrowed to 10 original articles that met the inclusion criteria. Here in, we list 16 genes which have driven nine special diseases, two of which (JAK, CD207) encode atopic dermatitis, two genes trigger vitiligo (IFIH1, TICAM1), two genes role in multiple sclerosis (CD80, CD86), a pathway of three genes activate ankylosing spondylitis (HLA-B27-ERAP1), a gene link to breast cancer (EMSY), a gene associate with gastric cancer (MMP-7), two genes relate to colorectal cancer (miR-143/145, KRAS), three genes play the role in chronic prostatitis/chronic pelvic pain syndrome (IFNG, IFNGR1, AR), and a gene rule on arterial hypertension (TBX2). Last, our discovery provides new insight into the development of novel medications that act on specific druggable target genes that have not previously been investigated.